# A Study of BGM0504 in Early T2DM With Obesity

> **NCT07743983** · PHASE3 · RECRUITING · sponsor: **BrightGene Bio-Medical Technology Co., Ltd.** · enrollment: 372 (estimated)

## Conditions studied

- Type 2 Diabetes (T2DM)

## Interventions

- **DRUG:** BGM0504
- **DRUG:** semaglutide

## Key facts

- **NCT ID:** NCT07743983
- **Lead sponsor:** BrightGene Bio-Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 372 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743983, "A Study of BGM0504 in Early T2DM With Obesity". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*